Genomic Cancer Panel and Profiling Market - A Global and Regional Analysis: Focus on Tissue Testing, Cancer Panel Type, Cancer Type, Application, Technology, End User, and Region - Analysis and Forecast, 2023-2033

Report
198 Pages
December 2023
Region: Global
BIS Research
ID: 5914408

The global genomic cancer panel and profiling market is expected to reach $26.59 billion by 2033 from $9.90 billion in 2022. The global genomic cancer panel and profiling market is expected to grow at a robust rate of 9.43% during the forecast period 2023-2033. This growth is driven by advancements in genomic research and an increasing focus on precision medicine within the field of oncology.

Introduction to Genomic Cancer Panel and Profiling

Genomic cancer panels and profiling represent a modern approach to detecting cancer by studying the genetic details of tumors before symptoms appear. The significant advantages of employing these panels lie in their ability to provide comprehensive genetic insights, facilitating early detection and the formulation of personalized treatment plans. The genomic cancer panel and profiling market is on the rise due to the transformative potential these technologies hold in reshaping cancer management. By enhancing the understanding of cancer genetics, these panels offer a more precise means of identifying specific genetic alterations, enabling healthcare professionals to tailor interventions accordingly.

The global genomic cancer panel and profiling market has significant growth, attributed to the increasing demand for early cancer detection while treating cancer patients. The increasing popularity and appreciation of liquid biopsy tests have also played a critical role in the market growth. Furthermore, the increased cancer risk due to the changing lifestyle of people is also influencing the market growth.

Impact

The genomic cancer panel and profiling market has made an impact in the following ways:

Personalized Treatment:

Doctors can use these panels to find specific changes in a person's cancer genes. This helps create treatments that are just for that person and the type of cancer.

Finding Cancer Early:

The panels can also help catch cancer early by spotting certain gene markers linked to different cancers. Finding cancer early makes it easier to treat and beat.

Helping Doctors Choose Treatments:

Doctors can make better choices about treatments using genetic info. They can pick treatments that work well and skip ones that might not help as much.

Research and Testing New Treatments:

The genetic info from these panels helps researchers find new ways to treat cancer. It's also useful for testing new drugs in trials.

Clinical Trials and Research:

Genomic cancer profiling has contributed significantly to the identification of new therapeutic targets. This information is crucial for the development of novel drugs and the design of clinical trials, ultimately advancing cancer research and treatment options.

Prognostic Information:

Genomic profiling can provide insights into the aggressiveness of a particular cancer and help predict the likelihood of recurrence. This information assists in developing appropriate follow-up plans and adjusting treatment strategies.

Cost-Efficiency:

Advances in genomic sequencing technologies have led to a decrease in the cost of genomic profiling. This makes it more accessible to a larger patient population, allowing more individuals to benefit from personalized cancer treatment.

Market Segmentation:

Segmentation 1: by Tissue Testing

Solid Tissue Testing
Liquid Tissue Testing

Liquid tissue testing is becoming the primary method in the global genomic cancer panel and profiling market, particularly when it comes to testing tissues. This means that using liquid samples for testing, rather than traditional methods, is expected to become more common and important in understanding and treating cancer.

Segmentation 2: by Cancer Panel Type

Single-Gene Panel
Multi-Gene Panel

Multi-gene panel segment dominated the global genomic cancer panel and profiling market (by cancer panel type) in FY2022. These panels, which examine multiple genes simultaneously, are taking a leading role in shaping the understanding and analysis of cancer at the genomic level on a global scale.

Segmentation 3: by Cancer Type

Lung Cancer
Breast Cancer
Colon Cancer
Prostate Cancer
Other Cancers

Breast cancer dominated the global genomic cancer panel and profiling market (by cancer type) in FY2022. Breast cancer is one of the most common types of cancer globally, with a high incidence rate. The large number of cases makes it a key focus for genomic profiling efforts.

Segmentation 4: by Application

Clinical
Research

Clinical segment dominated the global genomic cancer panel and profiling market (by application) in FY2022. Genomic cancer panels provide critical information that helps clinicians make more informed decisions about the most effective treatments for individual patients. This personalized approach enhances the overall efficacy of cancer care.

Segmentation 5: by Technology

Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescence In-Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Others

Next-Generation Sequencing (NGS) segment dominated the global genomic cancer panel and profiling market (by technology) in FY2022. NGS offers comprehensive, cost-effective, and efficient genomic analysis, making it a preferred technology for researchers and clinicians in the field of cancer genomics.

Segmentation 6: by End User

Hospitals
Clinical and Diagnostic Laboratories
Research and Academic Institutes
Other End Users

Hospitals segment dominated the global genomic cancer panel and profiling market (by end user) in FY2022. Hospitals often have multidisciplinary teams of healthcare professionals, including oncologists, pathologists, and genetic counselors. This collaborative approach is essential for the effective utilization of genomic information in cancer care.

Segmentation 7: by Region

North America
Europe
Asia-Pacific
Latin America
Rest-of-the-World

Based on region, North America dominated the global genomic cancer panel and profiling market in terms of market size in FY2022. However, the Asia-Pacific region, encompassing numerous emerging economies, is projected to exhibit a CAGR of 11.81% during the forecast period from 2023 to 2033.

Recent Developments in the Global Genomic Cancer Panel and Profiling Market

In April 2023, Agilent Technologies, Inc. introduced the NGS assay, SureSelect Cancer CGP, to advance precision oncology through comprehensive genomic profiling (CGP). This assay expands the range of biomarkers available for solid tumor profiling with a rapid and highly efficient workflow.
In January 2023, FOUNDATION MEDICINE, INC. (F. Hoffmann-La Roche Ltd) got FDA approval for its FoundationOne Liquid CDx test as a companion diagnostic for Rozlytrek. This test is relevant for ROS1+NSCLC patients and NTRK fusion-positive solid tumors patients.
In October 2023, Invitae Corporation. received FDA market authorization for its Common Hereditary Cancers Panel. This achievement marks the first FDA-approved broad panel designed to detect germline variants linked to hereditary cancers.
In February 2023, Exact Sciences Corp. introduced the OncoExTra therapy selection test in the U.S. OncoExTra is an advanced next-generation sequencing (NGS) genomic test that encompasses both DNA and RNA analysis, offering a comprehensive molecular profile of the patient's cancer. This test furnishes precise and actionable personalized results for doctors and their patients.
In January 2023, F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.), in partnership with Natera, Inc., launched a FoundationOne Tracker early access program for clinical use, which is a personalized circulating tumor DNA (ctDNA) monitoring assay. The test investigational use version is now available for clinical trials.
In April 2023, Agilent and Theragen Bio successfully partnered to advance bioinformatic solutions for cancer genomic profiling in South Korea. This collaboration integrated Agilent's SureSelect Cancer CGP assay with Theragen Bio's localized analysis software, leading to a transformation in translational research and a substantial boost in precision oncology within the region.
In July 2023, Illumina Inc. and Pillar Biosciences Inc. formed a strategic partnership to offer Pillar's oncology assays worldwide as part of Illumina's oncology products. This collaboration provides advanced next-generation sequencing solutions, improving the efficiency and cost-effectiveness of oncology testing for personalized cancer treatment.
In January 2022, Thermo Fisher Scientific, Inc. made an agreement with Oncocyte Corporation for the distribution of Thermo Fisher Scientific, Inc.'s two IVD assays on Thermo Fisher Scientific's Ion Torrent Genexus System. Oncocyte Corporation will also validate the company's Oncomine Comprehensive assay plus on the Genexus system.

Demand - Drivers, Restraints, and Opportunities

Market Driver:

Rising Need for Cancer Profiling in Developed Countries Drives Demand for Genomic Panels and Profiling Tests: Developed countries often have aging populations, where a larger proportion of individuals are in the elderly age group. Cancer incidence tends to increase with age, and as the population ages, the overall burden of cancer rises. This demographic trend drives a steady demand for cancer treatment and related healthcare services. Genomic cancer panels contribute to this by helping identify genetic markers associated with early-stage cancers. Early detection allows for timely and targeted interventions, potentially improving treatment outcomes and reducing the overall burden of the disease.

Market Restraint:

Significant Implications of Reimbursement Reductions Impacting Growth of the Genomic Cancer Panel and Profiling Market: Reimbursement reductions in the genomic cancer panel and profiling market have significant implications for both healthcare providers and patients. These reductions often lead to reduced financial support for these valuable diagnostic tests. As a result, healthcare providers may face challenges in offering these tests to patients, potentially limiting their accessibility.

Market Opportunity:

Robust Pipeline of Genomic Cancer Panels and Profiling Tests Poised to Revolutionize Cancer Diagnosis: Genomic cancer panel and profiling tests are an emerging field in health technology that has the potential to disrupt the traditional models of cancer screening. With these tests, a single and non-invasive blood test can assess multiple cancer types at once, with the help of which more cancer can be detected at an earlier stage when accompanied by screening programs. The technology is still in its developmental stage, and there are numerous tests presently under development with self-funded research. Additionally, very few of these tests are FDA-approved, and most of them are being prescribed as laboratory-developed tests that do not require FDA approvals.

How can this report add value to an organization?

Product/Innovation Strategy: The global genomic cancer panel and profiling market has been extensively segmented based on various categories, such as tissue testing, cancer panel type, cancer type, application, technology, end user, and region. This can help readers get a clear overview of the segments accounting for the largest share and the ones that are well-positioned to grow in the coming years.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

Detailed secondary research was performed to ensure maximum coverage of manufacturers/suppliers operational in a country.
Exact revenue information, up to a certain extent, was extracted for each company from secondary sources and databases. The revenues related to the product and end user were estimated for each market player based on fact-based proxy indicators as well as primary inputs.
The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of genomic cancer panels and profiling.
The market contribution of the genomic cancer panel and profiling anticipates the launch of products in the future, which has been calculated based on historical analysis. This analysis has been supported by proxy factors such as the innovation scale of the companies, the status of funding, collaborations, customer base, and patent scenario.
The scope of availability of genomic cancer panels and profiling in a particular region has been assessed based on a comprehensive analysis of companies’ prospects, the regional end-user perception, and other factors impacting the launch of products in that region.
The base year considered for the calculation of the market size is 2022. A historical year analysis has been done for the period FY2018-FY2021. The market size has been estimated for FY2022 and projected for the period FY2023-FY2033.
Revenues of the companies have been referenced from their annual reports for FY2021 and FY2022. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, product approval status, market collaborations, and operational history.
Regional distribution of the market revenue has been estimated based on the companies in each region and the adoption rate of advance dental and robotics solutions. All the numbers have been adjusted to a single digit after the decimal for better presentation in the report. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the period 2023-2033.
The market has been mapped based on the available genomic cancer panel and profiling. All the key companies with significant offerings in this field have been considered and profiled in this report.
Market strategies and developments of key players have been considered for the calculation of the potential of the market in the forecast period.

Primary Research:

The primary sources involve industry experts in the global genomic cancer panel and profiling market, including the market players offering genomic cancer panels and profiling. Resources such as COOs, vice presidents, product managers, directors, and territory managers have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

Validation and triangulation of all the numbers and graphs
Validation of the report’s segmentation and key qualitative findings for advance dental and robotics solutions
Understanding the competitive landscape and business model
Current and proposed production values of a product by market players
Validation of the numbers of the different segments of the market in focus
Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

Centers for Disease Control and Prevention (CDC), American Dental Association (ADA), World Health Organization (WHO), and National Center for Biotechnology Information, among others
Annual reports, SEC filings, and investor presentations of the leading market players
Company websites and detailed study of their portfolios
Gold standard magazines, journals, whitepapers, press releases, and news articles
Databases

The key data points taken from the secondary sources include:

Segmentation and percentage share estimates
Company and country understanding and data for market value estimation
Key industries/market trends
Developments among top players
Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names in this market are:

Agilent Technologies, Inc.
ARUP Laboratories
Burning Rock DX
Caris Life Sciences
Thermo Fisher Scientific, Inc.
Danaher Corporation (Integrated DNA Technologies, Inc.)
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd
Fulgent Genetics
Genecast Biotechnology Co., Ltd
Illumina, Inc.
Invitae Corporation

This product will be delivered within 3-5 business days.

1 Markets

1.1 Product Definition
1.2 Inclusion and Exclusion Criteria
1.2.1 Inclusion Criteria
1.2.2 Exclusion Criteria
1.3 Market Scope
1.3.1 Scope of the Study
1.3.2 Key Questions Answered in this Report
1.4 Research Methodology
1.4.1 Global Genomic Cancer Panel and Profiling Market: Research Methodology
1.4.2 Data Sources
1.4.3 Market Estimation Model
1.4.4 Criteria for Company Profiling
1.5 Market Overview
1.5.1 Market Definition
1.5.2 Market Footprint and Growth Potential
1.5.3 Future Potential

2 Industry Analysis

2.1 Legal Requirements
2.1.1 Regulation of Genetic Tests
2.1.2 NCCN Guidelines
2.1.3 Reimbursement Scenario
2.2 Patent Analysis
2.2.1 Patent Filing Trend
2.2.2 Patent Analysis (by Year)
2.2.3 Patent Analysis (by Country)

3 Market Dynamics

3.1 Overview
3.1.1 Impact Analysis
3.2 Market Drivers
3.2.1 Rising Need for Cancer Profiling in Developed Countries Driving Demand for Genomic Panels and Profiling Tests
3.2.2 Increase in Genomic Research Funding Expanding the Market for Genomic Cancer Panels and Profiling
3.2.3 Technological Advancements in the Field of Informatics Expanding Consumer Reach
3.3 Market Restraints
3.3.1 Significant Implications of Reimbursement Reductions Impacting Growth of the Genomic Cancer Panel and Profiling Market
3.3.2 Impact of High-Cost Pressure Hindering Development in Genomic Cancer Panel and Profiling Testing
3.4 Market Opportunities
3.4.1 Robust Pipeline of Genomic Cancer Panels and Profiling Tests Poised to Revolutionize Cancer Diagnosis
3.4.2 Discovery of New Biomarkers Presents an Opportunity for the Development of Diagnostics Tools and Technologies

4 Competitive Insights

4.1 Overview
4.2 Key Strategies and Developments
4.2.1 Product Launches, Approvals, and Upgradations
4.2.2 Synergistic Activities
4.2.3 Mergers and Acquisitions
4.2.4 Business Expansions, Funding, and Licenses
4.3 Growth-Share Analysis
4.3.1 Growth-Share Analysis (by Technology), 2022

5 By Tissue Testing

5.1 Overview
5.2 Solid Tissue Testing
5.3 Liquid Tissue Testing

6 By Cancer Panel Type

6.1 Overview
6.2 Single-Gene Panel
6.3 Multi-Gene Panel

7 By Cancer Type

7.1 Overview
7.2 Lung Cancer
7.3 Breast Cancer
7.4 Colon Cancer
7.5 Prostate Cancer
7.6 Other Cancers

8 By Application

8.1 Overview
8.2 Clinical
8.2.1 By Clinical
8.3 Research

9 By Technology

9.1 Overview
9.2 Next-Generation Sequencing (NGS)
9.3 Polymerase Chain Reaction (PCR)
9.4 Fluorescence In-Situ Hybridization (FISH)
9.5 Immunohistochemistry (IHC)
9.6 Others

10 By End User

10.1 Overview
10.2 Research and Academic Institutes
10.3 Clinical and Diagnostic Laboratories
10.4 Hospitals
10.5 Other End Users

11 By Region

11.1 Overview
11.2 North America
11.2.1 Key Dynamics
11.2.2 U.S.
11.2.3 Canada
11.3 Europe
11.3.1 Key Dynamics
11.3.2 Germany
11.3.3 France
11.3.4 U.K.
11.3.5 Italy
11.3.6 Spain
11.3.7 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 Key Dynamics
11.4.2 China
11.4.3 Japan
11.4.4 India
11.4.5 Australia
11.4.6 South Korea
11.4.7 Rest-of-Asia-Pacific
11.5 Latin America
11.5.1 Key Dynamics
11.5.2 Brazil
11.5.3 Mexico
11.5.4 Rest-of-Latin America
11.6 Rest-of-the-World
11.6.1 Key Dynamics

12 Company Profiles

12.1 Overview
12.2 Agilent Technologies, Inc.
12.2.1 Company Overview
12.2.2 Role of Agilent Technologies, Inc. in the Global Genomic Cancer Panel and Profiling Market
12.2.3 Corporate Strategies
12.2.4 Financials
12.2.5 Analyst Perspective
12.3 ARUP Laboratories
12.3.1 Company Overview
12.3.2 Role of ARUP Laboratories in the Global Genomic Cancer Panel and Profiling Market
12.3.3 Corporate Strategies
12.3.4 Analyst Perspective
12.4 Burning Rock DX
12.4.1 Company Overview
12.4.2 Role of Burning Rock DX in the Global Genomic Cancer Panel and Profiling Market
12.4.3 Business Strategies
12.4.4 Analyst Perspective
12.5 Caris Life Sciences
12.5.1 Company Overview
12.5.2 Role of Caris Life Sciences in the Global Genomic Cancer Panel and Profiling Market
12.5.3 Corporate Strategies
12.5.4 Analyst Perspective
12.6 Danaher Corporation (Integrated DNA Technologies, Inc.)
12.6.1 Company Overview
12.6.2 Role of Danaher Corporation (Integrated DNA Technologies, Inc.) in the Global Genomic Cancer Panel and Profiling Market
12.6.3 Financials
12.6.4 Analyst Perspective
12.7 Exact Sciences Corporation
12.7.1 Company Overview
12.7.2 Role of Exact Sciences Corporation in the Global Genomic Cancer Panel and Profiling Market
12.7.3 Corporate Strategies
12.7.4 Business Strategies
12.7.5 Financials
12.7.6 Analyst Perspective
12.8 F. Hoffmann-La Roche Ltd
12.8.1 Company Overview
12.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Genomic Cancer Panel and Profiling Market
12.8.3 Corporate Strategies
12.8.4 Business Strategies
12.8.5 Financials
12.8.6 Analyst Perspective
12.9 Fulgent Genetics
12.9.1 Company Overview
12.9.2 Role of Fulgent Genetics in the Global Genomic Cancer Panel and Profiling Market
12.9.3 Financials
12.9.4 Analyst Perspective
12.1 Genecast Biotechnology Co., Ltd
12.10.1 Company Overview
12.10.2 Role of Genecast Biotechnology Co., Ltd in the Global Genomic Cancer Panel and Profiling Market
12.10.3 Analyst Perspective
12.11 Illumina, Inc.
12.11.1 Company Overview
12.11.2 Role of Illumina, Inc. in the Global Genomic Cancer Panel and Profiling Market
12.11.3 Corporate Strategies
12.11.4 Business Strategies
12.11.5 Financials
12.11.6 Analyst Perspective
12.12 Invitae Corporation
12.12.1 Company Overview
12.12.2 Role of Invitae Corporation in the Global Genomic Cancer Panel and Profiling Market
12.12.3 Corporate Strategies
12.12.4 Financials
12.12.5 Key Insights about the Financial Health of the Company
12.12.6 Analyst Perspective
12.13 Laboratory Corporation of America Holdings.
12.13.1 Company Overview
12.13.2 Role of Laboratory Corporation of America Holdings. in Global Genomic Cancer Panel and Profiling Market
12.13.3 Corporate Strategies
12.13.4 Business Strategies
12.13.5 Financials
12.13.6 Analyst’s Perspective
12.14 Paragon Genomics
12.14.1 Company Overview
12.14.2 Role of Paragon Genomics in the Global Genomic Cancer Panel and Profiling Market
12.14.3 Analyst Perspective
12.15 Tempus
12.15.1 Company Overview
12.15.2 Role of Tempus in the Global Genomic Cancer Panel and Profiling Market
12.15.3 Analyst Perspective
12.16 Thermo Fisher Scientific Inc.
12.16.1 Company Overview
12.16.2 Role of Thermo Fisher Scientific Inc. in the Global Genomic Cancer Panel and Profiling Market
12.16.3 Financials
12.16.4 Analyst Perspective

List of Figures

Figure 1: Global Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 2: Global Genomic Cancer Panel and Profiling Market (by Tissue Testing), % Share, 2022 and 2033
Figure 3: Global Genomic Cancer Panel and Profiling Market (by Cancer Panel Type), % Share, 2022 and 2033
Figure 4: Global Genomic Cancer Panel and Profiling Market (by Cancer Type), % Share, 2022 and 2033
Figure 5: Global Genomic Cancer Panel and Profiling Market (by Application), % Share, 2022 and 2033
Figure 6: Global Genomic Cancer Panel and Profiling Market (by Technology), % Share 2022 and 2033
Figure 7: Global Genomic Cancer Panel and Profiling Market (by End User), % Share 2022 and 2033
Figure 8: Global Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
Figure 9: Global Genomic Cancer Panel and Profiling Market Segmentation
Figure 10: Global Genomic Cancer Panel and Profiling Market: Research Methodology
Figure 11: Primary Research Methodology
Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
Figure 13: Top-Down Approach (Segment-Wise Analysis)
Figure 14: Genomic Cancer Panel and Profiling Workflow, End User Perspective
Figure 15: Genomic Cancer Panel and Profiling Workflow, Laboratory Technician Perspective
Figure 16: Global Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 17: General Testing Criterion According to the NCCN Guidelines
Figure 18: Reimbursement Components in the U.S.
Figure 19: Global Genomic Cancer Panel and Profiling Market, Patent Analysis (by Year), January 2020-October 2023
Figure 20: Global Genomic Cancer Panel and Profiling Market, Patent Analysis (by Country), January 2020-October 2023
Figure 21: Global Genomic Cancer Panel and Profiling Market Dynamics
Figure 22: Cancer Profiling Cases in Developed Countries
Figure 23: Share of Global Cancer Prevalence, 2010-2019
Figure 24: Share of Global Age-Standardized Death Rate of Cancer, 2010-2019
Figure 25: Genomic Research Funding by National Human Genome Research Institute (NHGRI), $Million, 2020, 2021, and 2022
Figure 26: Key Players Offering
Figure 27: Reimbursement Reductions Adopted for Oncology Testing as per PAMA Revisions
Figure 28: Cost Difference between the Multi-Gene Panel Test and Usual Care Screening Test
Figure 29: Share of Key Developments, January 2020-October 2023
Figure 30: Number of Product Launches, Approvals, and Upgradations (by Company), January 2020-October 2023
Figure 31: Growth-Share Analysis of the Global Genomic Cancer Panel and Profiling Market (by Technology), 2022
Figure 32: Global Genomic Cancer Panel and Profiling Market (by Tissue Testing)
Figure 33: Global Genomic Cancer Panel and Profiling Market (by Tissue Testing), % Share, 2022 and 2033
Figure 34: Global Genomic Cancer Panel and Profiling Market (Solid Tissue Testing), $Billion, 2022-2033
Figure 35: Global Genomic Cancer Panel and Profiling Market (Liquid Tissue Testing), $Billion, 2022-2033
Figure 36: Global Genomic Cancer Panel and Profiling Market (by Cancer Panel Type)
Figure 37: Global Genomic Cancer Panel and Profiling Market (by Cancer Panel Type), % Share, 2022 and 2033
Figure 38: Global Genomic Cancer Panel and Profiling Market (Single-Gene Panel), $Billion, 2022-2033
Figure 39: Global Genomic Cancer Panel and Profiling Market (Multi-Gene Panel), $Billion, 2022-2033
Figure 40: Global Genomic Cancer Panel and Profiling Market (by Cancer Type)
Figure 41: Global Genomic Cancer Panel and Profiling Market (by Cancer Type), % Share, 2022 and 2033
Figure 42: Global Genomic Cancer Panel and Profiling Market (Lung Cancer), $Billion, 2022-2033
Figure 43: Global Genomic Cancer Panel and Profiling Market (Breast Cancer), $Billion, 2022-2033
Figure 44: Global Genomic Cancer Panel and Profiling Market (Colon Cancer), $Billion, 2022-2033
Figure 45: Estimated New Cancer Cases and Deaths for Prostate Cancer, 2022
Figure 46: Global Genomic Cancer Panel and Profiling Market (Prostate Cancer), $Billion, 2022-2033
Figure 47: Global Genomic Cancer Panel and Profiling Market (Other Cancers), $Billion, 2022-2033
Figure 48: Global Genomic Cancer Panel and Profiling Market (by Application)
Figure 49: Global Genomic Cancer Panel and Profiling Market (by Application), % Share, 2022 and 2033
Figure 50: Global Genomic Cancer Panel and Profiling Market (Clinical), $Billion, 2022-2033
Figure 51: Global Genomic Cancer Panel and Profiling Market (by Clinical), $Million, 2022-2033
Figure 52: Global Genomic Cancer Panel and Profiling Market (Research), $Billion, 2022-2033
Figure 53: Global Genomic Cancer Panel and Profiling Market (by Technology)
Figure 54: Global Genomic Cancer Panel and Profiling Market (by Technology), % Share, 2022 and 2033
Figure 55: Global Genomic Cancer Panel and Profiling Market (Next-Generation Sequencing), $Billion, 2022-2033
Figure 56: Global Genomic Cancer Panel and Profiling Market (Polymerase Chain Reaction), $Billion, 2022-2033
Figure 57: Global Genomic Cancer Panel and Profiling Market (Fluorescence In-Situ Hybridization), $Billion, 2022-2033
Figure 58: Global Genomic Cancer Panel and Profiling Market (Immunohistochemistry), $Billion, 2022-2033
Figure 59: Global Genomic Cancer Panel and Profiling Market (Others), $Billion, 2022-2033
Figure 60: Global Genomic Cancer Panel and Profiling Market (by End User)
Figure 61: Global Genomic Cancer Panel and Profiling Market (by End User), % Share 2022 and 2033
Figure 62: Global Genomic Cancer Panel and Profiling Market (Research and Academic Institutes), $Billion, 2022-2033
Figure 63: Global Genomic Cancer Panel and Profiling Market (Clinical and Diagnostics Laboratories), $Billion, 2022-2033
Figure 64: Global Genomic Cancer Panel and Profiling Market (Hospitals), $Billion, 2022-2033
Figure 65: Global Genomic Cancer Panel and Profiling Market (Other End Users), $Billion, 2022-2033
Figure 66: Global Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
Figure 67: North America Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 68: North America Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
Figure 69: North America Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
Figure 70: North America Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
Figure 71: U.S. Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 72: Canada Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 73: Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 74: Europe Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
Figure 75: Europe Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
Figure 76: Europe Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
Figure 77: Germany Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 78: France Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 79: U.K. Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 80: Italy Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 81: Spain Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 82: Rest-of-Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 83: Asia-Pacific Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 84: Asia-Pacific Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
Figure 85: Asia-Pacific Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
Figure 86: Asia-Pacific Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
Figure 87: China Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 88: Japan Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 89: India Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 90: Australia Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 91: South Korea Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 92: Rest-of-Asia-Pacific Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 93: Latin America Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
Figure 94: Latin America Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
Figure 95: Latin America Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
Figure 96: Latin America Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
Figure 97: Brazil Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 98: Mexico Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 99: Rest-of-Latin America Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 100: Rest-of-the-World Genomic Cancer Panel and Profiling Market, $Million, 2022-2033
Figure 101: Rest-of-the-World Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
Figure 102: Rest-of-the-World Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
Figure 103: Global Genomic Cancer Panel and Profiling Market, Total Number of Companies Profiled
Figure 104: Agilent Technologies, Inc.: Product Portfolio
Figure 105: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
Figure 106: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 107: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 108: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 109: ARUP Laboratories: Overall Product Portfolio
Figure 110: Burning Rock DX: Product Portfolio
Figure 111: Caris Life Sciences: Overall Product Portfolio
Figure 112: Danaher Corporation (Integrated DNA Technologies, Inc.): Product Portfolio
Figure 113: Danaher Corporation (Integrated DNA Technologies, Inc.): Overall Financials, $Million, 2020-2022
Figure 114: Danaher Corporation (Integrated DNA Technologies, Inc.): Revenue (by Segment), $Million, 2020-2022
Figure 115: Danaher Corporation (Integrated DNA Technologies, Inc.): Revenue (by Region), $Million, 2020-2022
Figure 116: Danaher Corporation (Integrated DNA Technologies, Inc.): R&D Expenditure, $Million, 2020-2022
Figure 117: Exact Sciences Corporation: Product Portfolio
Figure 118: Exact Sciences Corporation: Overall Financials, $Million, 2019-2021
Figure 119: Exact Sciences Corporation: Revenue (by Segment), $Million, 2019-2021
Figure 120: Exact Sciences Corporation: Revenue (by Region), $Million, 2019-2021
Figure 121: Exact Sciences Corporation: R&D Expenditure, $Million, 2019-2021
Figure 122: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 123: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
Figure 124: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
Figure 125: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
Figure 126: Fulgent Genetics: Product Portfolio
Figure 127: Fulgent Genetics: Overall Financials, $Million, 2020-2022
Figure 128: Fulgent Genetics: Revenue (by Region), $Million, 2020-2022
Figure 129: Fulgent Genetics: R&D Expenditure, $Million, 2020-2022
Figure 130: Genecast Biotechnology Co., Ltd: Product Portfolio
Figure 131: Illumina, Inc.: Product Portfolio
Figure 132: Illumina, Inc.: Overall Financials, $Million, 2020-2022
Figure 133: Illumina, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 134: Illumina, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 135: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 136: Invitae Corporation: Overall Product Portfolio
Figure 137: Invitae Corporation: Overall Financials, $Million, 2020-2022
Figure 138: Invitae Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 139: Invitae Corporation: Revenue (by Region), $Million, 2020-2022
Figure 140: Invitae Corporation: R&D Expenditure, $Million, 2020-2022
Figure 141: Laboratory Corporation of America Holdings.: Product Portfolio
Figure 142: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2020-2022
Figure 143: Laboratory Corporation of America Holdings.: Revenue (by Segment), $Million, 2020-2022
Figure 144: Laboratory Corporation of America Holdings.: Revenue (by Region), $Million, 2020-2022
Figure 145: Paragon Genomics: Product Portfolio
Figure 146: Tempus: Product Portfolio
Figure 147: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 148: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 149: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 150: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 151: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022

List of Tables

Table 1: Global Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 2: Technological Trends in the Global Genomic Cancer Panel and Profiling Market
Table 3: Global Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 4: Global Genomic Cancer Panel and Profiling Market, Pipeline Tests
Table 5: Ongoing Cancer-Based Biomarkers Trials
Table 6: North America Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 7: Europe Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 8: Asia-Pacific Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 9: Latin America Genomic Cancer Panel and Profiling Market, Impact Analysis
Table 10: Rest-of-the-World Genomic Cancer Panel and Profiling Market, Impact Analysis

Executive Summary

The global genomic cancer panel and profiling market is estimated to reach $26.59 billion by 2033, reveals the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 9.43% during the forecast period 2023-2033.

The global genomic cancer panel and profiling market has significant growth, attributed to the increasing demand for early cancer detection while treating cancer patients. The increasing popularity and appreciation of liquid biopsy tests have also played a critical role in the market growth. Furthermore, the increased cancer risk due to the changing lifestyle of people is also influencing the market growth.

USP of the Report

Key trends
Regulatory framework
Market dynamics, including drivers, restraints, and opportunities
Region and country-level analysis, including market size and forecast
Cross-segmentation at the region level
Detailed segmentation

Analyst Perspective

According to Swati Sood, Principal Analyst, 'Global genomic cancer panel and profiling market is a rapidly emerging market and is expected to revolutionize the field of oncology field in the coming years due to the continuous increase in the demand for cancer diagnosis and industrial analysis.'

Key Companies Profiled

The key players profiled in the report include Agilent Technologies, Inc., ARUP Laboratories, Burning Rock DX, Caris Life Sciences, Thermo Fisher Scientific, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Fulgent Genetics, Genecast Biotechnology Co., Ltd, Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings., Paragon Genomics, and Tempus

Key Questions Answered in the Report

How is the genomic cancer panel and profiling market revolutionizing cancer detection, treatment, and other applications landscapes?
What are the major market drivers, challenges, and opportunities in the global genomic cancer panel and profiling market?
What are the underlying structures resulting in the emerging trends within the global genomic cancer panel and profiling market?
How did the COVID-19 pandemic impact the global genomic cancer panel and profiling market?
What are the key development strategies that are being implemented by major players to sustain themselves in the competitive market?
What are the key regulatory implications in developed and developing regions pertaining to the use of genomic cancer panels and profiling products?
What are the potential entry barriers that companies willing to enter a particular region in the market are expected to face?
What will be the growth rate of the global genomic cancer panel and profiling market during the forecast period?
How is each segment of the market expected to grow during the forecast period 2023-2033, and what revenue is anticipated to be generated by each of the segments?
What are the growth opportunities for the genomic cancer panel and profiling companies in the region of their operation?
Who are the leading players with significant offerings in the global genomic cancer panel and profiling market?
Which companies are anticipated to be highly disruptive in the future and why?

Companies Mentioned

Agilent Technologies, Inc.
ARUP Laboratories
Burning Rock DX
Caris Life Sciences
Danaher Corporation (Integrated DNA Technologies, Inc.)
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd
Fulgent Genetics
Genecast Biotechnology Co., Ltd
Illumina, Inc.
Invitae Corporation
Laboratory Corporation of America Holdings.
Paragon Genomics
Tempus
Thermo Fisher Scientific Inc.

Table Information

Report Attribute	Details
No. of Pages	198
Published	December 2023
Forecast Period	2023 - 2033
Estimated Market Value ( USD ) in 2023	$ 10.8 Billion
Forecasted Market Value ( USD ) by 2033	$ 26.59 Billion
Compound Annual Growth Rate	9.4%
Regions Covered	Global
No. of Companies Mentioned	15

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€4836EUR$4,950USD£4,038GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€7474EUR$7,650USD£6,240GBP